Erlotinib Tablet, Film Coated
Product Images NDC 72485-218

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Erlotinib (NDC 72485-218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clin-1 (Cur 1)

Kaplan-Meier curves depicting investigator-assessed progression-free survival (PFS) in a study comparing Erlotinib versus chemotherapy. The y-axis shows progression-free survival probability from 0 to 1.0, and the x-axis shows duration in months up to 45. Two curves are plotted: a solid line representing Erlotinib and a dashed line for chemotherapy. Below the graph, the number of patients at risk at various time points is listed for both treatment groups.*

FDA Label Image

Clin-2 (Cur 2)

Kaplan-Meier survival curves depicting overall survival probability over months for patients in Study 3, comparing Erlotinib versus placebo treatment groups. The x-axis represents overall survival in months, and the y-axis shows survival probability. Patient numbers at risk are listed below the graph for both treatment groups across time intervals.*

FDA Label Image

Cli-3 (Cur 3)

Kaplan-Meier survival curves comparing overall survival probability over time (in months) between patients treated with Erlotinib and Placebo in a clinical study. The graph displays survival probability on the vertical axis and overall survival in months on the horizontal axis, with patient numbers at risk for each group indicated below the time axis.*

FDA Label Image

Clin-4 (Cur 4)

Kaplan-Meier survival curves chart illustrating overall survival over months for the 100 mg Erlotinib cohort compared to placebo in Study 5. The graph shows survival probability on the vertical axis and overall survival in months on the horizontal axis, including patient risk numbers for both Erlotinib and placebo groups at various time points.*

FDA Label Image

Er-des (Des 1)

Chemical structure of erlotinib hydrochloride, showing its molecular arrangement with methoxyethoxy groups attached to a quinazoline core linked to a substituted phenyl ring containing a nitrile group.*

FDA Label Image

Erlt-100 (Erl 100)

Packaging label for Erlotinib Tablets 100 mg film-coated oral tablets. The carton contains 30 tablets and displays the NDC 72485-218-30. Manufactured by Shilpa Medicare Limited, India, and distributed by Armas Pharmaceuticals Inc., USA. Includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.